Skip to main content

Table 2 Best overall response

From: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

a
  DL 1
4 mg/kg
N = 3
DL 2
8 mg/kg
N = 3
DL 3
16 mg/kg
N = 3
DL 4
32 mg/kg
N = 6
Overall
N = 15
Stable disease (N, %) 3 (100%) 2 (67%) 2 (67%) 4 (67%) 11 (73%)
Progressive disease (N, %) 0 (0%) 1 (33%) 1 (33%) 2 (33%) 4 (27%)
b
Patient # Tumor type Dose (mg/kg) Time on study (months)* Best response Off treatment reason IL-8 level decrease
1 Colorectal 4 3.5 SD Patient choice  
2 Prostate 4 2 SD Patient choice x
3 Chordoma 4 8 SD Patient choice  
4 Chordoma 8 13 SD Patient choice  
5 Colorectal 8 1.5 PD Progression  
6 Esophageal 8 7 SD Progression x
7 Chondrosarcoma 16 1 PD Progression x
8 Chordoma 16 5.5 SD Progression  
9 Chordoma 16 5.5 SD Patient choice x
10 Papillary thyroid 32 5.5 SD Patient choice x
11 Colorectal 32 4.5 SD Patient choice x
12 Prostate 32 8 SD Patient choice x
13 Colorectal 32 7 SD Patient choice x
14 Ovarian 32 1.5 PD Progression x
15 Chordoma 32 2 PD Progression x
  1. Best overall response. a Best overall response by dose level and overall are shown. b Responses are shown by tumor type and dose level in addition to time on study and reason for withdrawal from study treatment. Three patients had adverse events leading to their decision to come off the study. Decreases in IL-8 are also noted
  2. DL dose level; IL-8 interleukin-8; SD stable disease; PD progressive disease